Group 1 - The core viewpoint of the news highlights the recent decline in the stock price of CanSino Biologics, which has dropped 2.27% to 74.99 CNY per share, with a total market capitalization of 18.556 billion CNY and a cumulative decline of 5.27% over three consecutive days [1] - CanSino Biologics, established on January 13, 2009, and listed on August 13, 2020, specializes in the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards, with 97.84% of its revenue coming from vaccine sales [1] Group 2 - Longxin Fund has a significant holding in CanSino, with its Longxin Healthcare Mixed Fund (LOF) A holding 35,200 shares, representing 2.07% of the fund's net value, ranking as the tenth largest holding [2] - The Longxin Healthcare Mixed Fund (LOF) A has experienced a year-to-date return of 22.89% and a one-year return of 18.56%, with a total fund size of 128 million CNY [2] - The fund manager, Yuan Jie, has been in position for 211 days, with the best fund return during this period being 66.29% and the worst being -3.63% [2]